ALT down big again. I bought a little I agree there may be room to mitigate some AEs w titration as you say but also dose reduction (it wasn’t allowed in the phase 2). They could carve out a niche here w any small differences in the profile and given the size of the overall market that could be valuable.
Market Data 
Markets 
AI
